FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2487561900> ?p ?o ?g. }

• W2487561900 abstract "The prevalence of type 2 diabetes (T2DM) in younger adults is growing. Compared to the late onset T2DM, it is well recognized that the disease tends to behave more aggressively in the younger age group with evidence of premature micro and macrovasular diseases and shorter life span. This increased mortality is largely attributed to cardiovascular complications. In a recent pilot study, young adults with T2DM were found to have significantly lower peak diastolic strain rate (PEDSR) on cardiac MRI (CMR), a forerunner of diabetic cardiomyopathy. Liraglutide, a glucagon like peptide-1 (GLP-1) analogue, is one of the new classes of glucose lowering therapies licensed to be used in management of T2DM. In randomised controlled trials, liraglutide improves glycaemic control by 1–1.5 % with an added benefit of weight loss of 2–3 kg. In addition, there is emerging evidence elucidating the cardioprotective effects of GLP-1 analogues independent of glycaemic control. In a small study, liraglutide has also been shown to improve cardiac function in patients with coronary ischaemia or congestive heart failure. This is a prospective, randomised, open-label, blind end-point (PROBE) active-comparator trial. A total of 90 obese eligible participants with T2DM (18–50 years) will be randomised to either liraglutide 1.8 mg once daily or sitagliptin 100 mg once daily for 26 weeks. The primary aim is to assess whether liraglutide improves diastolic function compared to sitagliptin as measured by PEDSR using CMR. Although newer classes of GLP-1 analogues are made available in recent years, there are very few published studies demonstrating the beneficial effect of GLP-1 analogues on cardiovascular endpoints. In a recently published LEADER study, liraglutide has shown superiority to placebo in a population of type 2 diabetes with high risk of cardiovascular disease. To the best of our knowledge, there are no published studies establishing the effect of liraglutide on cardiac function in younger patients with T2DM on a larger scale. The LYDIA study will comprehensively describe changes in various parameters of cardiac structure and function in patients treated with liraglutide aiming to provide new evidence on effect of liraglutide on diastolic function in young obese people with T2DM. Trial Registration ClinicalTrials.gov identifier: NCT02043054" @default.
• W2487561900 created "2016-08-23" @default.
• W2487561900 creator A5011282084 @default.
• W2487561900 creator A5015345040 @default.
• W2487561900 creator A5027073118 @default.
• W2487561900 creator A5042443875 @default.
• W2487561900 creator A5045843829 @default.
• W2487561900 creator A5051363076 @default.
• W2487561900 creator A5068804442 @default.
• W2487561900 creator A5084593004 @default.
• W2487561900 date "2016-07-21" @default.
• W2487561900 modified "2023-09-25" @default.
• W2487561900 title "Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study)" @default.
• W2487561900 cites W1513319197 @default.
• W2487561900 cites W1856267101 @default.
• W2487561900 cites W1965260787 @default.
• W2487561900 cites W1968315455 @default.
• W2487561900 cites W1970571657 @default.
• W2487561900 cites W1973958666 @default.
• W2487561900 cites W1979612559 @default.
• W2487561900 cites W1983000201 @default.
• W2487561900 cites W2003380560 @default.
• W2487561900 cites W2004877549 @default.
• W2487561900 cites W2017258148 @default.
• W2487561900 cites W2019861564 @default.
• W2487561900 cites W2028732281 @default.
• W2487561900 cites W2051279660 @default.
• W2487561900 cites W2054564814 @default.
• W2487561900 cites W2056952313 @default.
• W2487561900 cites W2060762923 @default.
• W2487561900 cites W2061691264 @default.
• W2487561900 cites W2064130493 @default.
• W2487561900 cites W2064328585 @default.
• W2487561900 cites W2070647639 @default.
• W2487561900 cites W2072203364 @default.
• W2487561900 cites W2072455721 @default.
• W2487561900 cites W2074658648 @default.
• W2487561900 cites W2086170960 @default.
• W2487561900 cites W2089142428 @default.
• W2487561900 cites W2091801540 @default.
• W2487561900 cites W2096940071 @default.
• W2487561900 cites W2097187491 @default.
• W2487561900 cites W2117405666 @default.
• W2487561900 cites W2117828918 @default.
• W2487561900 cites W2126115073 @default.
• W2487561900 cites W2127854619 @default.
• W2487561900 cites W2137784332 @default.
• W2487561900 cites W2141971513 @default.
• W2487561900 cites W2142097676 @default.
• W2487561900 cites W2142830692 @default.
• W2487561900 cites W2146051421 @default.
• W2487561900 cites W2146199058 @default.
• W2487561900 cites W2146264128 @default.
• W2487561900 cites W2151598759 @default.
• W2487561900 cites W2154279165 @default.
• W2487561900 cites W2154595662 @default.
• W2487561900 cites W2157166619 @default.
• W2487561900 cites W2159205789 @default.
• W2487561900 cites W2164255543 @default.
• W2487561900 cites W2282578582 @default.
• W2487561900 cites W2337454357 @default.
• W2487561900 cites W2425644022 @default.
• W2487561900 doi "https://doi.org/10.1186/s12933-016-0421-6" @default.
• W2487561900 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4955217" @default.
• W2487561900 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27440110" @default.
• W2487561900 hasPublicationYear "2016" @default.
• W2487561900 type Work @default.
• W2487561900 sameAs 2487561900 @default.
• W2487561900 citedByCount "11" @default.
• W2487561900 countsByYear W24875619002017 @default.
• W2487561900 countsByYear W24875619002018 @default.
• W2487561900 countsByYear W24875619002019 @default.
• W2487561900 countsByYear W24875619002020 @default.
• W2487561900 countsByYear W24875619002021 @default.
• W2487561900 crossrefType "journal-article" @default.
• W2487561900 hasAuthorship W2487561900A5011282084 @default.
• W2487561900 hasAuthorship W2487561900A5015345040 @default.
• W2487561900 hasAuthorship W2487561900A5027073118 @default.
• W2487561900 hasAuthorship W2487561900A5042443875 @default.
• W2487561900 hasAuthorship W2487561900A5045843829 @default.
• W2487561900 hasAuthorship W2487561900A5051363076 @default.
• W2487561900 hasAuthorship W2487561900A5068804442 @default.
• W2487561900 hasAuthorship W2487561900A5084593004 @default.
• W2487561900 hasBestOaLocation W24875619001 @default.
• W2487561900 hasConcept C111566952 @default.
• W2487561900 hasConcept C126322002 @default.
• W2487561900 hasConcept C134018914 @default.
• W2487561900 hasConcept C164705383 @default.
• W2487561900 hasConcept C168563851 @default.
• W2487561900 hasConcept C2776553924 @default.
• W2487561900 hasConcept C2777180221 @default.
• W2487561900 hasConcept C2778198053 @default.
• W2487561900 hasConcept C2778797674 @default.
• W2487561900 hasConcept C2779284873 @default.
• W2487561900 hasConcept C2781308992 @default.
• W2487561900 hasConcept C555293320 @default.
• W2487561900 hasConcept C71924100 @default.
• W2487561900 hasConceptScore W2487561900C111566952 @default.
• W2487561900 hasConceptScore W2487561900C126322002 @default.
• W2487561900 hasConceptScore W2487561900C134018914 @default.

• next